Open Access Case Report Article ID: IJICR-7-133

    A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge

    Emin Taşkıran*, Sevnaz Şahin, Sumru Savaş, Zeliha Fulden Saraç and Selahattin Fehmi Akçiçek

    Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection. 


    Published on: Oct 8, 2021 Pages: 24-25

    Full Text PDF Full Text HTML DOI: 10.17352/2455-8591.000033
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on IJICR

    Help ? Google Reviews 11